It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent.
To capitalise on the microbiome’s potential to improve human health, biotech and pharmaceutical companies are devoting greater resources to microbiome-related initiatives, spurring a spike in investments and collaborations.
Incorporating this potentially disruptive technology into the highly-structured process of drug discovery requires new approaches, thinking and tools.
By Dr Alexander C. Maue